Lifeboat Foundation

Triple-negative breast cancer (TNBC) is an aggressive tumor with a very poor prognosis and limited therapeutic targets. Now, researchers at Baylor College of Medicine and collaborating institutions have discovered in diverse TNBC animal models that targeting the protein elF4A with the small molecule drug Zotatifin suppressed tumor cell proliferation and remodeled the tumor immune microenvironment. The findings may lead to clinical trials to assess the potential patient benefits of this novel approach.

The team published their findings in The Journal of Clinical Investigation in an article titled, “Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.”

“Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy,” wrote the researchers. “Here, we show that therapeutically targeting the RNA helicase eIF4A by Zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic triple-negative breast cancer (TNBC) mouse models.”

Emmett Short discusses these comments on this episode of Lifespan News.

But first, the mad scientist David Sinclair, this time with Peter Diamandis at Abundance 360, giving more details into human trials for the genetic engineering side of the technology versus the chemical and pill side of the technology. Which would you want more? We’ll also hear David’s thoughts on how AI will affect the advancement of this tech. Spoiler: A lot. I’m going to play the best parts and add my commentary along the way.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
Telomere and Epigenetic Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

Continue reading “HbA1c: What’s Optimal, What’s My Data?” »

Music for pain relief and anxiety. I think somewhere else I read it helps heal brain injuries.

Further, subject-preferred music appears to induce a superior effect in relieving pain. This can be approached by allowing participants to select the most pleasant music from a prespecified list of songs or listen to their favorite music during the study. Nevertheless, the richness of emotions, meanings, and associations involved when listening to favorite music is poorly understood, especially regarding pain relief.

About the study

Continue reading “Study finds pleasurable music and ‘chills’ predict music-induced hypoalgesia” »

Cancer patients receiving anthracycline chemotherapy have more than twice the risk of developing heart failure compared to their peers without cancer.1The ground-breaking RESILIENCE project aims to prevent heart failure in patients who need anthracyclines to treat their cancer.

International experts and patients from the project gathered yesterday at the European Heart House, home of the European Society of Cardiology (ESC), as a unique think tank to improve the healthcare and quality of life for patients with cancer.

It is estimated that four million Europeans are diagnosed with cancer every year.2 Anthracycline chemotherapy has a prominent role in treating many forms of cancer-for example, up to 70% of patients with lymphoma receive an anthracycline regimen. Currently, there is no therapy to prevent anthracycline cardiotoxicity.

The Wistar Institute’s David B. Weiner and collaborators have engineered novel monoclonal antibodies that engage natural killer (NK) cells through a unique surface receptor that activates the immune system to fight against cancer.

In their publication titled, “Siglec-7 glyco-immune binding MAbs or NK cell engager biologics induce potent anti-tumor immunity against ovarian cancers,” published in Science Advances, the team demonstrates the preclinical feasibility of utilizing these new cancer immunotherapeutic approaches against diverse ovarian cancer types, including treatment-resistant and refractory ovarian cancers—alone or in combination with checkpoint inhibitor treatment.

The research started as a collaboration between Wistar’s Drs. Weiner and Mohamed Abdel-Mohsen, who were exploring the development of new glyco-signaling biologic tools that may be important in the fight against cancer.

Lung cancer is the third most common cancer in the U.S. and there have been more than 235,000 new cases of lung cancer in 2021. While this figure is significant, the rate of new lung and bronchus cancer cases is decreasing, in part because more people have stopped smoking. This trend, along with innovations in early detection and treatment, is also reducing the number of lung cancer deaths.

Dr. Robert Taylor Ripley, associate professor of surgery in the Division of General Thoracic Surgery, is an expert in mesothelioma and thoracic surgical oncology. In the following Q&A, he discusses common causes of lung cancer, risks and the latest treatments.

Q: What are the most common causes of lung cancer? A: Smoking cigarettes is the most common cause, but others include secondhand smoke and environmental inhalants. We see a fair number of patients with lung cancer who have never smoked. Exposure to diesel exhaust or other chemicals may also cause lung cancer in some non-smokers.

The large blue warning signs read “Video recording for fall detection and prevention” on the third-floor dementia care unit of the Trousdale, a private-pay senior living community in Silicon Valley where a studio starts from about $7,000 per month.

Continue reading “AI in Breast Radiology” »

An FDA advisory panel tended to embrace a new gene therapy treatment from Vertex and CRISPR for sickle cell anemia on Tuesday.